Longer-term impact of PCSK9 inhibitors on major adverse cardiovascular events and all-cause mortality: a systematic review and meta-analysis of randomised controlled trials

Back

ESC Professional Premium Access

Longer-term impact of PCSK9 inhibitors on major adverse cardiovascular events and all-cause mortality: a systematic review and meta-analysis of randomised controlled trials

Session: PCSK9 inhibitors and inclisiran

Topic: Lipid-Lowering Agents

Speaker: Ms J. Grover (Sydney, AU)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Ms Jahnavi Grover

Blacktown Hospital, Sydney (Australia)

0 follower

8 more presentations in this session

Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: a single country, multicenter, observational study (AT-TARGET-IT)

Speaker: Doctor C. Basile (Naples, IT)

Characteristics of patients initiating PCSK9i mAb following myocardial infarction and comparability of treatment groups in the Netherlands

Speaker: Doctor Q. Chan (Greater London, GB)

The effect of proprotein convertase subtilisin/kexin type 9 inhibition on the plasma proteome: a SPIRE sub-study

Speaker: Mr J. Kraaijenhof (Amsterdam, NL)

Efficacy and safety of alirocumab in children and adolescents with heterozygous familial hypercholesterolaemia inadequately controlled with statins

Speaker: Associate Professor R. Santos (Sao Paulo, BR)

Identification of potent small-molecule PCSK9 inhibitors based on quantitative structure-activity relationship, pharmacophore modeling, and molecular docking procedure.

Speaker: Professor M. Banach (Lodz, PL)

Access the full session

PCSK9 inhibitors and inclisiran

Speakers: Ms J. Grover, Doctor C. Basile, Doctor Q. Chan, Mr J. Kraaijenhof, Associate Professor R. Santos...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources